Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksJz Capital Regulatory News (JZCP)

Share Price Information for Jz Capital (JZCP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 215.00
Bid: 192.00
Ask: 238.00
Change: 0.00 (0.00%)
Spread: 46.00 (23.958%)
Open: 215.00
High: 216.00
Low: 215.00
Prev. Close: 215.00
JZCP Live PriceLast checked at -
JZ Capital Partners is an Investment Trust

The strategy is to realise investments, pay down debt and reduce commitments to new investments. In addition, the company will return capital to Shareholders while meeting the capital requirements of the portfolio in order to achieve NAV growth.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Q1 2017 Interim Management Statement

29 Jun 2017 07:00

JZ Capital Partners Ltd - Q1 2017 Interim Management Statement

JZ Capital Partners Ltd - Q1 2017 Interim Management Statement

PR Newswire

London, June 29

JZ CAPITAL PARTNERS LIMITED(a closed-end investment company incorporated with limited liability under the laws of Guernsey with registered number 48761)

 Q1 2017 Interim Management Statement29 June 2017

JZ Capital Partners Limited (LSE: JZCP.L, the “Company” or “JZCP”), the London listed fund that invests in US and European micro-cap companies and US real estate, today releases its Interim Management Statement for the period 1 March 2017 to 31 May 2017.

Results Highlights

Net Asset Value (“NAV”) of $833.3 million (28/02/17: $848.8 million) NAV per share of $9.93 (28/02/17: $10.12) $43.9 million invested during the period, including: $12.0 million invested in new co-investment Felix Storch $4.5 million follow-on investment in Jordan Health Products $1.2 million net investment in Reflective Apparel Factory (“RAF”), a Technical Services and Solutions (“TSS”) vertical add-on acquisition $16.3 million realised, including: $12.5 million from the first tranche of proceeds for Fidor Bank At the end of the period, the portfolio consisted of 34 micro-cap investments across nine industries and four major real estate “assemblages” (59 total properties) located in New York and South Florida

Strategic Initiatives

In May 2017, JZCP received shareholder approval for certain initiatives designed to maximize shareholder returns, including the discontinuation of the Company’s current dividend policy and inception of a new strategy to allow for the repurchase of shares In April 2017, JZCP increased its loan facility with Guggenheim Partners from approximately $100 million to $150 million in order to provide additional liquidity to JZCP in order to bridge certain planned realisations. The entire $150 million facility may be repaid, in whole or in part, with no penalty after June 2017

David Zalaznick, Founder and Investment Advisor of JZCP said: “Despite the challenging market environment, the strength of our balance sheet has again allowed us to put money to work across the US and European micro-cap and US real estate sectors.

We continue to believe that the US market presents a number of potential realisation opportunities for the Company and we remain confident in the outlook for our diversified portfolio.”

Net Asset Value

NAV per share for the quarter decreased from $10.12 to $9.93, or 1.9%.

NAV Returns

Net Asset Value per Ordinary Share as of 1 March 2017$10.12
Change in NAV per share due to capital gains and income received / accrued on investments
US Micro-cap0.03
European Micro-cap (0.05)
Real Estate (0.06)
Other Investment (0.06)
Other changes in NAV per share
Change in CULS Fair Value (0.01)
Finance Costs (0.06)
Foreign Exchange Effect0.08
Expenses and Taxation (0.04)
Net Asset Value per Ordinary Share as of 31 May 2017 $9.93

The US micro-cap portfolio had a net increase of 3 cents, primarily due to net accrued income of 5 cents and write-ups at our healthcare revenue cycle management vertical (2 cents) and logistics vertical (1 cent). Jordan Health Products was also written up 2 cents. An escrow payment related to our exited co-investment Medplast added 1 cent. Offsetting these uplifts in valuation were decreases in value at our legacy Nationwide Studios business (1 cent) and our ISS vertical (9 cents).

The European micro-cap portfolio had a net decrease of 5 cents, primarily due to 1cent of accrued income offset by a 6 cent write-down at Factor Energia.

The real estate portfolio had a net decrease of 6 cents, primarily due to estimates of debt service, operating costs and other expenses at the property level.

Finally, our other investments had a net decrease of 6 cents, primarily due to a write-down at Spruceview (6 cents).

The chart below summarises the cumulative total NAV returns and total shareholder returns for the most recent three-month, twelve-month, three-year and five-year period.

31/05/17Since 28/02/17Since 31/05/16Since 31/05/14Since 31/05/12
Share price (in GBP)£5.66£5.38£3.90£4.41£3.68
Dividends paid (in USD)$0.16$0.79$1.57
Total Shareholders' return (GBP)15.2%48.9%45.3%95.0%
NAV per share (in USD)$9.93$10.12$10.32$10.08$9.38
NAV per share total returns1(1.9)%(2.3)%6.5%24.2%
NAV to market price discount26%34%45%27%40%

______________

Total returns are cumulative and assume that dividends were reinvested

RECENT ACTIVITIES

Significant Investments and Realisations

US Micro-cap Investments – Verticals

TSS Vertical (formerly known as ‘testing’ vertical)

In May 2017, JZCP invested $1.2 million (investment net of proceeds from refinancing the entire testing vertical) to acquire RAF, which produces high-end reflective apparel purchased by transportation, municipal, construction and industrial customers.

US Micro-cap Investments – Co-investments

In March 2017, JZCP invested a further $4.5 million in Jordan Health Products, to fund the acquisition of Transtate, a business which sells, services, repairs and installs refurbished medical imaging equipment, specializing in catheter angiography equipment.

Also in March 2017, JZCP invested $12.0 million in Felix Storch, a business that manufactures and distributes specialty refrigeration products and appliances.

European Micro-cap Investments

In April and May 2017, JZCP made three short-term loans to EuroMicrocap Fund-B, L.P., totalling $5.4 million, to bridge investments in Docout, Ombuds and One World Packaging.

We expect these loans to be paid back before their stated maturity dates of 31 July 2017.

Real Estate Investments

In the three-month period ended 31 May 2017, JZCP invested a total of $10.4 million in follow-on investments in our Williamsburg Retail, Design District and Greenpoint properties.

Realisations

JZCP sold its interest in Fidor Bank (“Fidor”) to Groupe BPCE, the second largest banking group in France. The transaction closed in December 2016. JZCP invested a total of $13.8 million and is expected to receive total gross proceeds of approximately $25 million from the sale. JZCP received its first tranche of proceeds totalling $12.5 million in March 2017.

PORTFOLIO SUMMARY

At 31 May 2017, the Company’s portfolio consisted of 34 micro-cap investments across nine major industries and four major real estate “assemblages” (59 total properties) located in New York and South Florida.

($’000)At 31/05/17At 28/02/17% Gross Assets 31/05/17
US Micro-cap Portfolio442,147424,50238.9%
European Micro-cap Portfolio162,183154,27714.2%
Real Estate Portfolio474,758468,59941.7%
Other Portfolio15,84421,8021.4%
Total Private Investments1,094,9321,069,18096.2%
Cash42,26229,0643.7%
Total Investments (and Cash)1,137,1941,098,24499.9%
Other Current Assets5965110.1%
Total Investments (and Cash)1,137,7901,098,755100.0%

At 31 May 2017, 3.7% of gross assets were invested in “liquid” assets (cash). The remaining portion of the portfolio was invested in private investments in US or European micro-cap companies or real estate. These investments are valued at fair value by JZCP’s directors each quarter.

We value our privately held businesses carefully. Our average multiple used for our US micro-cap businesses is 8.2x trailing EBITDA. In addition, we do not have substantial debt in these businesses. The multiple of debt senior to JZCP’s position is approximately 3.4x EBITDA.

Top Ten Investments

Our ten largest investments as of 31 May 2017 are summarised below:

($000’s)Asset CategoryValuation 31/05/17% Gross Assets 31/05/17
Design District AssemblageReal Estate100,5708.8%
Industrial Services Solutions VerticalUS77,6536.8%
GreenpointReal Estate75,5246.6%
Healthcare Rev. Cycle Management VerticalUS70,2736.2%
Williamsburg RetailReal Estate68,7186.0%
Fulton AssemblageReal Estate62,0115.5%
EuroMicrocap Fund-C, L.P.European61,0775.4%
TierPointUS46,8134.1%
Jordan Health ProductsUS37,3543.3%
RedBridgeReal Estate36,4453.2%
Top Ten Investments636,43855.9%
Remaining Assets501,35244.1%
Gross Assets1,137,790100.0%

Balance Sheet

Below is a summary of JZCP’s balance sheet as of the relevant dates:

($000’s)31/05/1728/02/17
Cash and cash equivalents42,26229,064
Investments & other assets1,095,5281,069,691
(-) Other net liabilities(247,780)(195,976)
(-) ZDPs due 2022(56,669)(53,935)
Net Asset Value833,341848,844

At 31 May 2017, “other net liabilities” includes $60.2 million from the issuance of Convertible Unsecured Loan Stock (“CULS”) in July 2014, which carries an interest rate of 6%, and $147.6 million from a six-year term loan with Guggenheim Partners, which carries an interest rate of LIBOR plus 5.75%.

For Further Information:

Ed Berry / Kit Dunford +44 (0) 20 3727 1046 / 1143FTI Consulting

David Zalaznick +1 212 485 9410Jordan/Zalaznick Advisers, Inc.

Teresa Le Couteur-Tembo +44 (0) 1481 745741JZ Capital Partners, Ltd.

About JZCP

JZCP is a London listed fund which invests in US and European micro-cap companies and US real estate. Its objective is to achieve an overall return comprised of a current yield and capital appreciation. JZCP receives investment advice from Jordan/Zalaznick Advisers, Inc. (“JZAI”) which is led by David Zalaznick and Jay Jordan. They have worked together for 30 years and are supported by teams of investment professionals in New York, Chicago, London and Madrid. JZAI’s experts work with the existing management of micro-cap companies to help build better businesses, create value and deliver strong returns for investors. JZCP also invests in mezzanine loans, first and second lien investments and other publicly traded securities. For more information please visit www.jzcp.com.

Date   Source Headline
16th Oct 20137:00 amRNSDividend Declaration
16th Oct 20137:00 amRNSHalf Yearly Report
27th Sep 201310:45 amRNSNotice of Interim Results
4th Sep 20138:45 amRNSExpansion of European Portfolio
21st Aug 20139:00 amRNSNet Asset Value(s)
16th Jul 20137:00 amRNSNet Asset Value(s)
25th Jun 20137:00 amRNSInterim Management Statement
24th Jun 20136:15 pmRNSResult of AGM
28th May 20136:09 pmRNSReplacement - Net Asset Value(s)
28th May 20134:30 pmRNSNet Asset Value(s)
22nd May 20134:00 pmRNSNotice of AGM and Annual Accounts to NSM
22nd May 20131:30 pmRNSDirector/PDMR Shareholding
21st May 20138:08 amRNSFinal Results
21st May 20137:01 amRNSDividend Declaration
14th May 20137:00 amRNSNet Asset Value(s)
29th Apr 20139:48 amRNSDirector Change/Update
10th Apr 20139:43 amRNSNotice of Results
25th Mar 201311:15 amRNSNet Asset Value(s)
19th Feb 20136:15 pmRNSHolding(s) in Company
5th Feb 201312:48 pmRNSDirector Declaration
17th Jan 201310:00 amRNSNet Asset Value(s)
19th Dec 20125:17 pmRNSNet Asset Value(s)
19th Dec 20127:00 amRNSInterim Management Statement
19th Nov 201211:30 amRNSNet Asset Value(s)
14th Nov 20121:45 pmRNSDirector/PDMR Shareholding
30th Oct 20127:00 amRNSHalf Yearly Report to NSM
19th Oct 201212:03 pmRNSNet Asset Value(s)
10th Oct 20124:00 pmRNSDirector/PDMR Shareholding
10th Oct 201210:00 amRNSDividend Declaration
10th Oct 20127:00 amRNSInterim Results
25th Sep 201210:15 amRNSNet Asset Value(s)
21st Sep 20128:56 amRNSNotice of Results
4th Sep 20123:43 pmRNSChange of Registered Office and Service Provider
24th Aug 20129:16 amRNSNet Asset Value(s)
31st Jul 20124:32 pmRNSTotal Voting Rights
24th Jul 20129:26 amRNSHolding(s) in Company
23rd Jul 20124:30 pmRNSHolding(s) in Company
23rd Jul 20124:05 pmRNSNet Asset Value(s)
20th Jul 201210:21 amRNSTotal Voting Rights
5th Jul 20129:15 amRNSNet Asset Value(s)
4th Jul 20127:00 amRNSInterim Management Statement
3rd Jul 20124:47 pmRNSAnnual General Meeting
3rd Jul 20123:25 pmRNSResults of Second General Meeting
3rd Jul 201211:43 amRNSResults of First General Meeting
7th Jun 20129:36 amRNSNet Asset Value(s)
1st Jun 20124:55 pmRNSHolding(s) in Company
22nd May 201212:31 pmRNSDirector/PDMR Shareholding
18th May 20127:02 amRNSProposed admission and other strategic initiatives
18th May 20127:01 amRNSDividend declaration
18th May 20127:00 amRNSFull Year Results 2011

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.